vs
ARDELYX, INC.（ARDX）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
ARDELYX, INC.的季度营收约是READING INTERNATIONAL INC的1.9倍（$94.5M vs $50.3M），READING INTERNATIONAL INC净利率更高（-5.1% vs -39.8%，领先34.7%），ARDELYX, INC.同比增速更快（27.5% vs -14.2%），过去两年ARDELYX, INC.的营收复合增速更高（13.6% vs 5.6%）
Ardelyx是一家商业化阶段的生物制药企业，专注于研发和商业化针对胃肠道、心肾及代谢类疾病的创新疗法，其核心产品已在美国获批用于治疗便秘型肠易激综合征，同时拥有涵盖多适应症的各阶段研发管线。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
ARDX vs RDI — 直观对比
营收规模更大
ARDX
是对方的1.9倍
$50.3M
营收增速更快
ARDX
高出41.6%
-14.2%
净利率更高
RDI
高出34.7%
-39.8%
两年增速更快
ARDX
近两年复合增速
5.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $94.5M | $50.3M |
| 净利润 | $-37.6M | $-2.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -1.9% |
| 净利率 | -39.8% | -5.1% |
| 营收同比 | 27.5% | -14.2% |
| 净利润同比 | — | -14.5% |
| 每股收益（稀释后） | $-0.15 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARDXRDI
| Q1 26 | $94.5M | — | ||
| Q4 25 | $125.2M | $50.3M | ||
| Q3 25 | $110.3M | $52.2M | ||
| Q2 25 | $97.7M | $60.4M | ||
| Q1 25 | $74.1M | $40.2M | ||
| Q4 24 | $116.1M | $58.6M | ||
| Q3 24 | $98.2M | $60.1M | ||
| Q2 24 | $73.2M | $46.8M |
净利润ARDXRDI
| Q1 26 | $-37.6M | — | ||
| Q4 25 | $-407.0K | $-2.6M | ||
| Q3 25 | $-969.0K | $-4.2M | ||
| Q2 25 | $-19.1M | $-2.7M | ||
| Q1 25 | $-41.1M | $-4.8M | ||
| Q4 24 | $4.6M | $-2.2M | ||
| Q3 24 | $-809.0K | $-7.0M | ||
| Q2 24 | $-16.5M | $-12.8M |
毛利率ARDXRDI
| Q1 26 | — | — | ||
| Q4 25 | 91.3% | — | ||
| Q3 25 | 96.4% | — | ||
| Q2 25 | 87.3% | — | ||
| Q1 25 | 83.4% | — | ||
| Q4 24 | 84.3% | — | ||
| Q3 24 | 84.0% | — | ||
| Q2 24 | 87.1% | — |
营业利润率ARDXRDI
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | -1.9% | ||
| Q3 25 | 4.2% | -0.6% | ||
| Q2 25 | -14.7% | 4.8% | ||
| Q1 25 | -49.0% | -17.2% | ||
| Q4 24 | 7.0% | 2.6% | ||
| Q3 24 | 2.3% | -0.6% | ||
| Q2 24 | -18.6% | -16.4% |
净利率ARDXRDI
| Q1 26 | -39.8% | — | ||
| Q4 25 | -0.3% | -5.1% | ||
| Q3 25 | -0.9% | -8.0% | ||
| Q2 25 | -19.5% | -4.4% | ||
| Q1 25 | -55.5% | -11.8% | ||
| Q4 24 | 4.0% | -3.8% | ||
| Q3 24 | -0.8% | -11.7% | ||
| Q2 24 | -22.5% | -27.4% |
每股收益（稀释后）ARDXRDI
| Q1 26 | $-0.15 | — | ||
| Q4 25 | $-0.01 | $-0.11 | ||
| Q3 25 | $0.00 | $-0.18 | ||
| Q2 25 | $-0.08 | $-0.12 | ||
| Q1 25 | $-0.17 | $-0.21 | ||
| Q4 24 | $0.01 | $-0.11 | ||
| Q3 24 | $0.00 | $-0.31 | ||
| Q2 24 | $-0.07 | $-0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $238.1M | $10.5M |
| 总债务越低越好 | $203.5M | $185.1M |
| 股东权益账面价值 | $148.6M | $-18.2M |
| 总资产 | $504.5M | $434.9M |
| 负债/权益比越低杠杆越低 | 1.37× | — |
8季度趋势，按日历期对齐
现金及短期投资ARDXRDI
| Q1 26 | $238.1M | — | ||
| Q4 25 | $68.0M | $10.5M | ||
| Q3 25 | $42.7M | $8.1M | ||
| Q2 25 | $90.0M | $9.1M | ||
| Q1 25 | $30.8M | $5.9M | ||
| Q4 24 | $64.9M | $12.4M | ||
| Q3 24 | $47.4M | $10.1M | ||
| Q2 24 | $41.9M | $9.3M |
总债务ARDXRDI
| Q1 26 | $203.5M | — | ||
| Q4 25 | $202.8M | $185.1M | ||
| Q3 25 | $202.1M | — | ||
| Q2 25 | $201.4M | — | ||
| Q1 25 | $151.3M | — | ||
| Q4 24 | $150.9M | $202.7M | ||
| Q3 24 | $100.7M | — | ||
| Q2 24 | $100.2M | — |
股东权益ARDXRDI
| Q1 26 | $148.6M | — | ||
| Q4 25 | $166.9M | $-18.2M | ||
| Q3 25 | $154.3M | $-12.1M | ||
| Q2 25 | $139.5M | $-7.7M | ||
| Q1 25 | $145.7M | $-8.1M | ||
| Q4 24 | $173.3M | $-4.4M | ||
| Q3 24 | $158.3M | $1.6M | ||
| Q2 24 | $147.0M | $6.5M |
总资产ARDXRDI
| Q1 26 | $504.5M | — | ||
| Q4 25 | $501.6M | $434.9M | ||
| Q3 25 | $486.2M | $435.2M | ||
| Q2 25 | $466.8M | $438.1M | ||
| Q1 25 | $410.2M | $441.0M | ||
| Q4 24 | $435.8M | $471.0M | ||
| Q3 24 | $367.9M | $495.7M | ||
| Q2 24 | $343.5M | $494.9M |
负债/权益比ARDXRDI
| Q1 26 | 1.37× | — | ||
| Q4 25 | 1.21× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 1.44× | — | ||
| Q1 25 | 1.04× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $4.3M |
| 自由现金流经营现金流 - 资本支出 | — | $4.1M |
| 自由现金流率自由现金流/营收 | — | 8.2% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-2.9M |
8季度趋势，按日历期对齐
经营现金流ARDXRDI
| Q1 26 | — | — | ||
| Q4 25 | $21.0M | $4.3M | ||
| Q3 25 | $365.0K | $295.0K | ||
| Q2 25 | $-25.3M | $1.6M | ||
| Q1 25 | $-38.5M | $-7.7M | ||
| Q4 24 | $9.8M | $8.0M | ||
| Q3 24 | $501.0K | $1.3M | ||
| Q2 24 | $-19.4M | $-10.4M |
自由现金流ARDXRDI
| Q1 26 | — | — | ||
| Q4 25 | $20.6M | $4.1M | ||
| Q3 25 | $209.0K | $-246.0K | ||
| Q2 25 | $-26.0M | $1.2M | ||
| Q1 25 | $-38.8M | $-8.0M | ||
| Q4 24 | $9.2M | $7.0M | ||
| Q3 24 | $364.0K | $-1.1M | ||
| Q2 24 | $-19.5M | $-10.6M |
自由现金流率ARDXRDI
| Q1 26 | — | — | ||
| Q4 25 | 16.4% | 8.2% | ||
| Q3 25 | 0.2% | -0.5% | ||
| Q2 25 | -26.6% | 1.9% | ||
| Q1 25 | -52.3% | -19.8% | ||
| Q4 24 | 7.9% | 12.0% | ||
| Q3 24 | 0.4% | -1.8% | ||
| Q2 24 | -26.7% | -22.7% |
资本支出强度ARDXRDI
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 0.3% | ||
| Q3 25 | 0.1% | 1.0% | ||
| Q2 25 | 0.7% | 0.6% | ||
| Q1 25 | 0.4% | 0.6% | ||
| Q4 24 | 0.5% | 1.7% | ||
| Q3 24 | 0.1% | 4.0% | ||
| Q2 24 | 0.2% | 0.5% |
现金转化率ARDXRDI
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.11× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARDX
| IBSRELA | $70.1M | 74% |
| XPHOZAH | $23.3M | 25% |
| Non-cash royalty revenue related to the sale of future royalties | $695.0K | 1% |
| Product supply revenue | $354.0K | 0% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
